Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis

Fujii, Hideki; Enomoto, Masaru; Fukushima, Wakaba; Ohfuji, Satoko; Mori, Mami; Kobayashi, Sho; Iwai, Shuji; Morikawa, Hiroyasu; Tamori, Akihiro; Sakaguchi, Hiroki; Ikura, Yoshihiro; Ueda, Makiko; Kawada, Norifumi

doi:10.1007/s00535-009-0046-6

Cited by 38 publications

(27 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The platelet count has been included in many scoring systems for the noninvasive prediction of the severity of hepatic fibrosis in patients with chronic hepatitis C, and we have reported that noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C were also useful in patients with NASH [32]. In recent years Shah et al [33] reported the utility of a scoring system for NAFLD patients in a multicenter trial.…”

Section: Discussionmentioning

confidence: 98%

Platelet count for predicting fibrosis in nonalcoholic fatty liver disease

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Platelet count for predicting fibrosis in nonalcoholic fatty liver disease

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using this score, Calès et al reported an AUROC of 0.866 for significant fibrosis, 0.861 for severe fibrosis, and 0.842 for cirrhosis in a study of NAFLD subjects [102], although significantly lower values were obtained in other studies [101, 109, 110]. …”

Section: Diagnosis and Evaluation Of Nafldmentioning

confidence: 99%

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease

Obika

Noguchi

2012

Experimental Diabetes Research

214

180

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver function tests results, after the commonly investigated causes have been excluded, and frequently coexists with type 2 diabetes mellitus (T2DM) because the conditions have common risk factors. As both T2DM and NAFLD are related to adverse outcomes of the other, diagnosis and valuation of fatty liver is an important part of the management of diabetes. Although noninvasive methods, such as biomarkers, panel markers, and imaging, may support a diagnostic evaluation of NAFLD patients, accurate histopathological findings cannot be achieved without a liver biopsy. As it is important to know whether steatohepatitis and liver fibrosis are present for the management of NAFLD, liver biopsy remains the gold standard for NAFLD diagnosis and evaluation. Therefore, new investigations of the pathogenesis of NAFLD are necessary to develop useful biomarkers that could provide a reliable noninvasive alternative to liver biopsy.

show abstract

“…By the time a PN-patient has developed jaundice, there is a high likelihood of irreversible bridging fibrosis on liver biopsy [15]. In the adult population, many noninvasive measures of hepatic fibrosis have been developed for use in patients with known liver disease [16][17][18][19][20][21][22][23][24][25][26][27]. These tests allow progressive monitoring of liver disease with very low patient risk and have been shown to decrease rates of liver biopsies at centers where their use is routine.…”

mentioning

confidence: 98%